{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:22:22Z","timestamp":1774430542675,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Program of the network-type Joint Usage\/Research Center for Radiation Disaster Medical Science of Hiroshima University, Nagasaki University, and Fukushima Medical University"},{"name":"Wakunaga Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-98534-7","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T08:16:32Z","timestamp":1746692192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["(R)-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation"],"prefix":"10.1038","volume":"15","author":[{"given":"Hiroshi","family":"Ureshino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Ueshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Sanuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"98534_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo, C. D., Erba, H. P., Freeman, S. D. & Wei, A. H. Acute myeloid leukaemia. Lancet 401, 2073\u20132086 (2023).","journal-title":"Lancet"},{"key":"98534_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"98534_CR3","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti, A. et al. Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens. Haematologica 106, 894\u2013898 (2021).","journal-title":"Haematologica"},{"key":"98534_CR4","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood.2021014304","volume":"140","author":"D Thomalla","year":"2022","unstructured":"Thomalla, D. et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood 140, 2113\u20132126 (2022).","journal-title":"Blood"},{"key":"98534_CR5","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey, H. E. et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 8, 1566\u20131581 (2018).","journal-title":"Cancer Discov."},{"key":"98534_CR6","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3324\/haematol.2022.280631","volume":"108","author":"MA Fischer","year":"2023","unstructured":"Fischer, M. A. et al. Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes. Haematologica 108, 522\u2013531 (2023).","journal-title":"Haematologica"},{"key":"98534_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10637-023-01393-0","volume":"41","author":"T Mino","year":"2023","unstructured":"Mino, T. et al. A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia. Invest. New Drugs 41, 751\u2013760 (2023).","journal-title":"Invest. New Drugs"},{"key":"98534_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27\u201355 (1984).","journal-title":"Adv. Enzyme Regul."},{"key":"98534_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct. Target. Ther. 7, 51 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"98534_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei, S. et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 10, 536\u2013551 (2020).","journal-title":"Cancer Discov."},{"key":"98534_CR11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","volume":"38","author":"S Bhatt","year":"2020","unstructured":"Bhatt, S. et al. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. Cancer Cell 38, 872-890.e6 (2020).","journal-title":"Cancer Cell"},{"key":"98534_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"98534_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","volume":"2","author":"A Letai","year":"2002","unstructured":"Letai, A. et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183\u2013192 (2002).","journal-title":"Cancer Cell"},{"key":"98534_CR14","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.2147\/OTT.S194549","volume":"12","author":"X Li","year":"2019","unstructured":"Li, X. et al. Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia. Onco Targets Ther. 12, 3295\u20133304 (2019).","journal-title":"Onco Targets Ther."},{"key":"98534_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477\u2013482 (2016).","journal-title":"Nature"},{"key":"98534_CR16","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/ejh.13492","volume":"105","author":"M Hormi","year":"2020","unstructured":"Hormi, M. et al. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML. Eur. J. Haematol. 105, 588\u2013596 (2020).","journal-title":"Eur. J. Haematol."},{"key":"98534_CR17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/1078-0432.CCR-22-2088","volume":"29","author":"SI Tantawy","year":"2023","unstructured":"Tantawy, S. I. et al. Mechanisms of MCL-1 protein stability induced by MCL-1 antagonists in B-Cell malignancies. Clin. Cancer Res. 29, 446\u2013457 (2023).","journal-title":"Clin. Cancer Res."},{"key":"98534_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41392-025-02125-x","volume":"10","author":"X Hu","year":"2025","unstructured":"Hu, X. et al. Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia. Signal Transduct. Target. Ther. 10, 50 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"98534_CR19","doi-asserted-by":"publisher","first-page":"10491","DOI":"10.1074\/jbc.M412819200","volume":"280","author":"C Weng","year":"2005","unstructured":"Weng, C., Li, Y., Xu, D., Shi, Y. & Tang, H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J. Biol. Chem. 280, 10491\u201310500 (2005).","journal-title":"J. Biol. Chem."},{"key":"98534_CR20","doi-asserted-by":"publisher","first-page":"7993","DOI":"10.3390\/molecules27227993","volume":"27","author":"R Alaaeldin","year":"2022","unstructured":"Alaaeldin, R. et al. Dual topoisomerase I\/II inhibition-induced apoptosis and necro-apoptosis in cancer cells by a novel ciprofloxacin derivative via RIPK1\/RIPK3\/MLKL activation. Molecules 27, 7993. https:\/\/doi.org\/10.3390\/molecules27227993 (2022).","journal-title":"Molecules"},{"key":"98534_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canlet.2015.02.030","volume":"361","author":"F Stuhldreier","year":"2015","unstructured":"Stuhldreier, F. et al. Pleiotropic effects of spongean alkaloids on mechanisms of cell death, cell cycle progression and DNA damage response (DDR) of acute myeloid leukemia (AML) cells. Cancer Lett. 361, 39\u201348 (2015).","journal-title":"Cancer Lett."},{"key":"98534_CR22","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","volume":"16","author":"F Ravandi","year":"2015","unstructured":"Ravandi, F. et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 16, 1025\u20131036 (2015).","journal-title":"Lancet Oncol."},{"key":"98534_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0010186","volume":"5","author":"RE Hawtin","year":"2010","unstructured":"Hawtin, R. E. et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS ONE 5, 1\u201310 (2010).","journal-title":"PLoS ONE"},{"key":"98534_CR24","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba, H. P. et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1571\u20131583 (2023).","journal-title":"Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98534-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98534-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98534-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T08:16:37Z","timestamp":1746692197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98534-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["98534"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-98534-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HU reports personal fees from Novartis. TU, TY, MT, and YS are full-time employees of Wakunaga Pharmaceutical Co., Ltd. TI has received speaker honoraria from Novartis and research funding from Chugai Pharmaceutical Co. and Wakunaga Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The experiments were conducted in accordance with protocols approved by the Wakunaga Pharmaceutical Company Institutional Animal Care and Use Committee (Permission No. 375) and conform to the Guide for the Care and Use of Laboratory Animals published by the United States National Institute of Health. The study adhered to ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"16018"}}